Alnylam Pharmaceuticals to present new data on RNAi therapies for transthyretin amyloidosis and hypertension at 2024 AHA scientific sessions
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA)… read more.
